National Storage Mechanism | Additional information
RNS Number : 1653P
Silence Therapeutics PLC
05 June 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Silence Therapeutics Plc

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights


An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights          


Other (please specify)iii:


3. Details of person subject to the notification obligationiv

Name

Richard Griffiths and controlled undertakings

City and country of registered office (if applicable)

St Helier, Jersey

4. Full name of shareholder(s) (if different from 3.)v

Name


City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reachedvi:

1 June 2020

6. Date on which issuer notified (DD/MM/YYYY):

5 June 2020

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

28.40%

0.70%

29.10%

82,826,259

Position of previous notification (if

applicable)

27.94%

0.00%

27.94%


 

 

Place of completion

St Helier, Jersey, Channel Islands

Date of completion

5 June 2020

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLUVOVRRAUNRAR